Storage and Distribution of Cellular Therapy Products Autologous Service Provision

The Norfolk and Norwich University Hospitals NHS Foundation Trust is currently in the award stage of a procurement process entitled "Storage and Distribution of Cellular Therapy Products Autologous Service Provision," which falls under blood analysis services within the healthcare sector. This process, guided by the Health Care Services Provider Selection Regime Regulations 2023, has identified NHS Blood and Transplant (NHSBT) as the intended provider. The trust is based in Norwich, UK, and the region served is UKH1.

This contract, valued at approximately £200,000, is set to commence on 1st February 2026 and conclude on 31st March 2027. The procurement method used is a limited one, specifically an award procedure without a prior call for competition, due to its status as a Provider Selection Regime contract. This tender presents significant business growth opportunities, particularly for firms specialising in healthcare services and supply chain solutions.

NHSBT, known for their high standards in delivering services like CD34+ cell selection, will integrate well with existing healthcare initiatives at Norfolk and Norwich University Hospitals as well as James Paget University Hospital. This opportunity suits businesses that have proven capabilities in storage, processing, and the distribution of stem cells, and are able to provide value through innovative solutions and efficient service delivery. Additionally, companies focusing on contributing to social value and sustaining healthcare systems would find this contract aligns well with their operational goals.